| Publisher’s Note: Join us September 11-14 in Philadelphia for Digital Pharma East! We’re excited to announce our opening keynote, none other than Dustin Garis, world-renowned brand innovator, customer experience pioneer and Chief Troublemaker. Register today for the ultimate marketing event in the life sciences industry. |
Today's Big NewsAug 4, 2023 |
|
October 5-6, 2023 San Diego, CA Join us at the Fierce Medical Affairs Strategic Summit West and hear industry-leading speakers from Amgen, Abbott, Bayer, Gilead, Janssen, Otsuka, Daiichi Sankyo, and many more. Register now with early bird rates and save $200. .png) |
|
| By Annalee Armstrong Seagen is putting a phase 2 Merck-partnered antibody-drug conjugate on the shelf for now, nearly three years after signing on to a $1.6 billion partnership for the asset. |
|
|
|
| Philadelphia, PA |  |
|
|
By Max Bayer One of Amgen's top BiTE molecules continues to inch forward after the company posted a brief phase 2 readout Thursday. The trial update included no new data, but Amgen said tarlatamab posted better safety and efficacy data than it produced in phase 1. |
By James Waldron Mesoblast’s second attempt to win over regulators to its off-the-shelf cell therapy has had no more success than the first try, sinking the Australian biotech’s stock. |
By Helen Floersh The company is tripling down on its Alzheimer’s franchise, rounding out its tau-focused pipeline with a gene therapy aimed at amyloid-beta plaques. |
By Nick Paul Taylor Vir Biotechnology is narrowing its focus. Sitting on $1.9 billion, the infectious disease specialist has decided to stop work on its innate immunity small molecule platform as part of its efforts to “judiciously allocate” its capital. |
By Nick Paul Taylor Strike another hepatitis B drug candidate from Aligos Therapeutics’ once-stacked pipeline. The biotech kept up the cadence of program pruning by deciding against committing more cash to an siRNA prospect after getting a look at early-phase data. |
By Annalee Armstrong Gene editing biotech NeuBase Therapeutics is stopping program development and looking for a sale after its board of directors voted to close up shop and seek strategic alternatives. |
By Max Bayer,Gabrielle Masson,Annalee Armstrong CBER chief Peter Marks doesn't have any plans to leave the FDA—yet. Anthony Fauci's replacement at NIAID has been founf. Jamie Rubin takes CFO role at Boundless after EQRx stint. |
By Angus Liu Bristol Myers Squibb and BeiGene decided to terminate their three-drug licensing deal. Sumitomo Pharma's Otsuka-partnered schizophrenia candidate ulotaront failed in two phase 3 trials. AstraZeneca CEO responded to a report about the company's plan to spin out its China business. And more. |
By Teresa Carey This week on "The Top Line," we discuss how to support patients during the cancer drug shortage, plus this week's headlines. |
By Kevin Dunleavy A Louisiana woman is suing Novo Nordisk and Eli Lilly, alleging that her use of Ozempic and Mounjaro caused her to vomit so much that some of her teeth have fallen out. Jaclyn Bjorklund, 44, says that she also has been hospitalized on "several" occasions and that the companies failed to warn patients of “severe gastrointestinal events” that can be caused by using the injected drugs. |
By Noah Tong Society's biggest problems, like racism and gun violence, are wearing on the mental health of the country's youngest demographic. |
By Kevin Dunleavy When Amgen launched the first biosimilar to compete with AbbVie’s Humira in the U.S., the company looked forward to six months of exclusivity in competing one-on-one against the immunology powerhouse. But Thursday, Amgen reported second-quarter sales of just $19 million for Amjevita, a 63% drop sequentially. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss how to support patients during the cancer drug shortage, plus this week's headlines. |
|
|---|
|
|
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
